BioCentury
ARTICLE | Company News

Catalytica, Nabi deal

June 21, 1999 7:00 AM UTC

NABI acquired exclusive U.S. distribution rights to Aloprim intravenous allopurinol to control elevated uric acid levels in patients with leukemia, lymphoma and solid tumors. NABI, which will launch ...